TABLE 2.
Outcomes After Initiation of Vedolizumab for Pouchitis
| Duration of follow-up in years, median (IQR) | 1.3 (0.7–2.1) |
| Time until clinical response in years, median (IQR) | 0.3 (0.2–0.5) |
| Endoscopic Response, n (%) | |
| 3 months | 11/23 (47.8) |
| 6 months | 22/40 (55.0) |
| Ever | 40/74 (54.1) |
| Endoscopic Remission, n (%) | |
| 3 months | 3/23 (13.0) |
| 6 months | 6/40 (15.0) |
| Ever | 13/74 (17.6) |
| Corticosteroid-free response | 40/83 (48.2) |
| Corticosteroid-free remission | 14/83 (16.9) |
| Antibiotic and steroid free response | 21/83 (25.3) |
| Need for subsequent procedures | |
| Exam under anesthesia, n (%) | 12 (14.5) |
| Stricture dilation, n (%) | 16 (19.3) |
| Seton placement, n (%) | 7 (8.4) |
| Fistulotomy, n (%) | 2 (2.4) |
| Abscess drainage, n (%) | 4 (4.8) |
| Diverting ileostomy, n (%) | 4 (4.8) |
| Pouch excision, n (%) | 3 (3.6) |
| Corticosteroid prescription, n (%) | 28 (33.7) |
| Antibiotic prescription, n (%) | 50 (60.2) |
| Episodic, n (%) | 29 (34.9) |
| Continuous, n (%) | 22 (25.3) |
| Serious infection, n (%) a | 3 (3.6) |
| Relapse after initial response, n (%) | 16 (27.1) |
| Discontinuation of vedolizumab, n (%) b | 30 (36.1) |
aClostridium difficile infection, norovirus infection, intra-abdominal abscess requiring percutaneous drainage
bSee text for reasons for discontinuation.